5��14�꽡����ͯ������Ǵ�лָ����������

??Objective??To study the gender and age distribution of bone metabolic markers in healthy children and adolescents??5-14 years old??. Methods??Detailed clinical documents were collected??and morning fasting 5 mL venous blood samples were drawn from 273 cases of the healthy volunteers and healthy school children. Automatic electrochemiluminescence immunoassay analyzer was applied for the tests of bone formation markers??Procollagen type 1 nitrogenous propeptides??P1NP????Osteocalcin??OC???? and bone resorption marker??β-Cross-linked C-terminal telopeptide of type 1 collagen??β-CTx????. The bone metabolic markers were used to calculate percentile values for the 5th?? 10th?? 25th?? 50th?? 75th?? 90th?? and 95th percentiles in the 3 age groups respectively. Results??The variation trends of bone formation markers??P1NP??OC?? and bone resorption marker ??β-CTx?? in two gender groups were similar??being relatively low in preschool age and school age period??gradually increasing during preadolescence??reaching peak in adolescence and declining rapidly after adolescence. There were no significant differences in bone formation markers P1NP??P??0.404?? and OC ??P??0.766?? between male and female groups??but there was significant difference in bone resorption marker β-CTx??P??0.01??. Conclusion??There are no statistically significant differences in the serum levels of P1NP or OC between male and female groups in the bone formation markers of healthy children aged 5-14 years. There is significant difference in bone resorption marker β-CTx between the two groups??the level of the boys being higher than the girls. According to the age distribution of the reference values?? the increasing trend of bone metabolic parameters of the female group will appear 1 or 2 years earlier??the peak value being lower.     

Eighteen Months of Treatment With Subcutaneous Abaloparatide Followed by 6 Months of Treatment With Alendronate in Postmenopausal Women With Osteoporosis: Results of the ACTIVExtend Trial

Objective

To assess the efficacy and safety of 18 months of subcutaneous abaloparatide (ABL-SC) or placebo (PBO) followed by 6 months of alendronate (ALN) (preplanned interim analysis).

非胰岛素依赖型糖尿病患者血清PICP、ICTP测定及其与骨代谢的关系

目的　探讨非胰岛素依赖型糖尿病 (2型糖尿病 )对骨代谢的影响。　方法　对 30例 2型糖尿病患者及 40例正常人 (对照组 )血清 I型前胶原羧基末端前肽 (PICP)、I型胶原羧基吡啶并啉交联肽 (ICTP)、骨钙素(BGP)、钙 (Ca)、磷 (P)等骨代谢相关指标进行测定。　结果　 2型糖尿病患者血清 ICTP较对照组明显增高 (P<0 .0 1) ,PICP/ ICTP则较对照组明显降低 (P<0 .0 1) ,血清 PICP、BGP较对照组降低 ,但差异无显著性 (P>0 .0 5 ) ,血清 Ca、P与对照组无显著性差异。血清 ICTP与病程呈正相关 (r=0 .474,P<0 .0 1) ,血清 PICP与 BGP呈正相关(r=0 .5 89,P<0 .0 1)。　结论　 2型糖尿病患者骨吸收过程增加较为明显 ,造成骨量丢失。     

Comparison of Serum and Urine Assays for Biochemical Markers of Bone Resorption in Postmenopausal Women with and without Hormone Replacement Therapy and in Men

Biochemical markers of bone resorption have been used to characterize metabolic bone disease and assess therapeutic response. Most studies have used the urinary measurement of collagen crosslinks, but serum assays have recently been developed that may have less analytic and biologic variability. In the present study, we measured urine and serum N- and C-terminal crosslinked telopeptides of type I collagen (NTX and CTX) and serum bone sialoprotein (BSP) in postmenopausal women with or without hormone replacement therapy (HRT) and in men of similar age. In these populations, the variability of serum and urine markers was similar, except that serum NTX showed somewhat lower variability in postmenopausal women. Urine and serum assays correlated well with one another and were significantly lower in postmenopausal women on HRT compared with untreated women. The difference in women on HRT was similar for sNTX, uNTX and BSP (35–40%) and greater for sCTX and uCTX (52–53%). There was an inverse correlation between markers and bone mineral density, largely attributable to the high correlation in women not on HRT. Fractional excretion of NTX and CTX were estimated at 0.20 ± 0.07 and 0.44 ± 0.11, respectively. These values were independent of the concentration of the marker or of creatinine in the urine. We conclude that serum markers are useful measures of bone resorption in these populations, in whom the use of such markers is likely to be helpful in the management of osteoporosis. Received: 23 August 1999 / Accepted: 30 November 1999     

血清铁调素、PⅠNP、β-CTX在围绝经期骨质疏松症患者中的检测意义

目的探讨血清铁调素、Ⅰ型前胶原氨基端前肽(PⅠNP)、Ⅰ型原胶原C端肽β降解产物(β-CTX)在围绝经期骨质疏松症患者中的检测意义。方法选取2018年10月至2019年10月郑州市骨科医院收治的82例围绝经期骨质疏松症患者作为研究组,选取同期来院体检的50例健康围绝经期女性为对照组。检测两组血清铁调素、PⅠNP、β-CTX水平,并对其水平差异进行比较。结果研究组患者血清铁调素水平显著低于对照组(P<0.05),PⅠNP、β-CTX水平均高于对照组(P<0.05)。血清铁调素、PⅠNP和β-CTX联合诊断的AUC最高为0.932,诊断效能最高。结论围绝经期骨质疏松症患者血清铁调素水平降低,PⅠNP、β-CTX水平增高,血清铁调素、PⅠNP和β-CTX在围绝经期骨质疏松症的检测具有重要临床意义,且三者联合的诊断效能更高。     

阿托伐他汀对老年非缺血性心力衰竭患者心功能的影响

目的观察阿托伐他汀对老年非缺血性心力衰竭患者血浆肿瘤坏死因子-α(TNF-α)、白细胞介素-6(IL-6)、基质金属蛋白酶-9(MMP-9)和Ⅰ型胶原羧基端交联肽(CITP)水平的影响,探讨他汀类药物减少或延缓老年非缺血性心力衰竭发生和发展的可能机制。方法选择经冠状动脉造影证实的老年非缺血性心力衰竭患者38例作为研究对象,随机分为他汀类治疗组(阿托伐他汀10mg/d)及常规治疗组,每组19例。随访6个月,测定治疗前后患者血清TNF-α、IL-6、MMP-9和CITP的水平,并通过超声心动图观察治疗前后左心室射血分数(LVEF)及左心室大小。结果治疗过程中有1例患者因转氨酶增高停用阿托伐他汀治疗。2组治疗后血清TNF-α、IL-6、MMP-9和CITP水平与治疗前相比均下降(P<0.05)。治疗后治疗组血清TNF-α、IL-6、MMP9和CITP水平及LVEF明显低于对照组(P<0.01)。结论阿托伐他汀可以降低非缺血性心力衰竭患者血清TNF-α、IL-6、MMP-9和CITP的水平,延缓老年非缺血性心力衰竭的发生发展。